Medical device company ResMed (NYSE:RMD) in Q3 CY2025, with sales up 9.1% year on year to $1.34 billion. Its non-GAAP profit ...

ResMed (RMD) came out with quarterly earnings of $2.55 per share, beating the Zacks Consensus Estimate of $2.49 per share. This compares to earnings of $2.2 per share a year ago. These figures are ...

Resmed reported revenue of $1.9 billion for the first quarter of fiscal year 2026, a 9% increase compared to the same period in 2025.

As Philips’ recall of many of its CPAP and BiPAP machines and other respiratory devices grew to include more machines and sparked tens of thousands of patient complaints, ResMed stepped up to fill ...

Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to ...

SAN DIEGO (AP) — SAN DIEGO (AP) — ResMed Inc. (RMD) on Thursday reported fiscal first-quarter net income of $348.5 million. On a per-share basis, the San Diego-based company said it had net income of ...

ResMed (NYSE:RMD) intends to keep its CPAP masks that utilize magnets on the market despite a recall because it regards the action as a labeling correction rather than a product removal. According to ...

Medical device company ResMed (NYSE:RMD) will be reporting earnings this Thursday afternoon. Here’s what investors should know. ResMed met analysts’ revenue expectations last quarter, reporting ...

The last 12 months have been nothing short of a whirlwind for ResMed. After finding itself scrambling to pick up the slack left in the wake of Philips’ massive respiratory device recall last June, it ...

SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2025 on Thursday, ...

Please note, Resmed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only. A replay of the earnings webcast will be accessible on ...